VYGR - Voyager Therapeutics, Inc.
NEXT EARNINGS:
Mar 10, 2026
(in 13 days)
EPS Est: $-0.54
|
Rev Est: $10.5M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$14.40
DETAILS
HIGH:
$18.00
LOW:
$8.00
MEDIAN:
$18.00
CONSENSUS:
$14.40
UPSIDE:
280.95%
Market Cap:
210.17M
Volume:
531,691
Avg Volume:
540,665
52 Week Range:
2.65-5.55
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.33
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
172
IPO Date:
2015-11-11
EPS (TTM):
-1.13
P/E Ratio:
-5.03
Revenue (TTM):
80.00M
Total Assets:
393.05M
Total Debt:
43.73M
Cash & Equiv:
71.37M
Rev Growth (5Y):
-5.2%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-24.3%
Debt/Equity:
0.15
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-10 | $-0.47 | $-0.53 | +11.3% | $13.4M | $10.5M | +27.4% |
| 2025-08-06 | $-0.57 | $-0.48 | -18.7% | $5.2M | $7.9M | -33.8% |
| 2025-05-06 | $-0.53 | $-0.35 | -51.4% | $6.5M | $13.9M | -53.5% |
| 2025-03-11 | $-0.59 | $-0.35 | -68.6% | $6.3M | $12.9M | -51.5% |
| 2024-11-12 | $-0.16 | $-0.45 | +64.4% | $24.6M | $15.5M | +59.4% |
| 2024-08-06 | $-0.18 | $-0.38 | +52.6% | $29.6M | $9.5M | +212.7% |
| 2024-05-13 | $-0.20 | $-0.44 | +54.5% | $19.5M | $9.4M | +107.4% |
| 2024-02-28 | $1.25 | $-0.29 | +531.0% | $90.1M | $20.6M | +336.6% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 80.00M | 250.01M | 40.91M | 37.41M | 171.13M | 104.39M | 7.62M | 10.13M | 14.22M | 17.33M | 0 | 0 |
| Net Income | (65.00M) | 132.33M | (46.41M) | (71.20M) | 36.74M | (43.60M) | (88.29M) | (70.70M) | (40.19M) | (29.67M) | (16.32M) | (7.67M) |
| EPS | -1.13 | 3.08 | -1.21 | -1.75 | 0.99 | -1.14 | -2.75 | -2.64 | -1.59 | -7.08 | -1.11 | -16.55 |
| Total Assets | 393.05M | 351.28M | 159.36M | 193.85M | 261.58M | 354.76M | 177.03M | 184.48M | 189.57M | 229.46M | 11.50M | 149,000 |
| Total Debt | 43.73M | 20.29M | 23.13M | 44.18M | 47.61M | 34.17M | 0 | 0 | 0 | 0 | 6.30M | 2.93M |
| Cash & Equivalents | 71.37M | 68.80M | 98.96M | 117.43M | 104.44M | 86.04M | 46.86M | 31.53M | 36.64M | 31.31M | 7.04M | 135,000 |
| Operating Cash Flow | (15.31M) | 77.92M | (12.51M) | (53.52M) | (96.72M) | 48.67M | (15.89M) | (61.35M) | (42.48M) | 41.30M | (11.92M) | (5.45M) |
| Free Cash Flow | (18.83M) | 74.66M | (15.00M) | (55.13M) | (108.81M) | 40.95M | (20.19M) | (65.33M) | (47.51M) | 40.27M | (14.91M) | (5.45M) |
| FCF per Share | -0.33 | 1.74 | -0.39 | -1.46 | -2.93 | 1.14 | -0.63 | -2.44 | -1.88 | 9.61 | -1.01 | -11.77 |
| Book Value | 299.76M | 236.32M | 59.02M | 95.06M | 154.32M | 99.51M | 46.45M | 134.05M | 135.92M | 169.07M | 1.15M | (3.83M) |
| Cash & ST Investments | 266.68M | 230.88M | 118.85M | 132.54M | 181.14M | 281.53M | 155.81M | 169.05M | 174.42M | 224.34M | 7.04M | 135,000 |
| ROC Equity | -0.22 | 0.56 | -0.79 | -0.75 | 0.24 | -0.44 | -1.90 | -0.53 | -0.30 | -0.18 | -14.20 | N/A |